Biosimilars in the Evolving Cancer Care Landscape: Experts Address Current Questions, Controversies, and Impact on Clinical Practice

In this online educational program, Jeffrey Crawford, MD, Lee Schwartzberg, MD, FACP, and Andrew D. Zelenetz, MD, PhD, explore the impact of biosimilar oncology drugs on patient care and discuss current questions regarding the use of these agents in clinical practice.

Downloadable Slideset

In this downloadable slideset from the NCCN Biosimilars symposium, Andrew D. Zelenetz, MD, PhD, Jeffrey Crawford, MD, and Lee S. Schwartzberg, MD, FACP, provide expert perspective on integrating biosimilar drugs into your practice to improve the care of patients with cancer.

Released: March 8, 2018
Jointly provided by the National Comprehensive Cancer Network and Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

This activity is supported by educational grants from
Amgen
Pfizer Inc.
Sandoz Inc., a Novartis Division

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue